Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > BUSINESS
BUSINESS
- Amicus to Enroll PIII Study for Pompe Therapy AT-GAA by Year-End: COO
June 10, 2019
- Napabucasin PIII Colorectal Cancer Trial to Continue: Sumitomo Dainippon
June 10, 2019
- Keytruda Tops Drug Sales Ranking in May: Encise Snapshot
June 10, 2019
- Pfizer Keeps Diverse Portfolio Strategy amid Sluggish Bavencio, Oncology Chief Says I/O Just One Area of Cancer Care
June 10, 2019
- Oral MDS Treatment ASTX727 Equivalent to IV Dacogen in PIII Study: Otsuka
June 10, 2019
- Taiho to Commercialize Otsuka US Subsidiary’s 2 Cancer Drugs in North America
June 10, 2019
- Konica Minolta Joins Hands with Univ. of Tokyo, NCC on Genetic Profiling
June 7, 2019
- Royalties Push Up Profits at 3 Major Makers, Shionogi Sees 40% Operating Margin This Year
June 7, 2019
- Boehringer’s Japan Pharma Sales on Course for Recovery; Jardiance, Spiolto Upbeat
June 7, 2019
- Astellas Ties Up with Microsoft to Develop Tool Using “Mixed Reality” to Improve Medication Adherence
June 7, 2019
- Fujifilm Toyama Chemical’s T-817MA Enters PII to Examine Post-Stroke Rehabilitation Enhancement Effects
June 7, 2019
- Takeda Calls Off PIII Study of Sakigake-Designated Ninlaro for AL Amyloidosis after Failing to Hit Primary Goal
June 7, 2019
- Merck SVP Roy Baynes Recounts Keytruda Development, Says We Followed Science
June 6, 2019
- Japan Fair Trade Watchdog Issues Cease and Desist and Surcharge Payment Orders to Koa Isei for Price Fixing
June 6, 2019
- Otsuka Chemical Acquires Cefixime-Related Business from Astellas
June 6, 2019
- Fujifilm Develops Continuous Production System for Biologics, Set to Begin Contract Manufacturing in 2020
June 6, 2019
- Fujifilm Invests 200 Million Yen in Cell Therapy Startup
June 5, 2019
- Xofluza Hits Goal of Preventing Flu Onset in Japan PIII: Shionogi
June 5, 2019
- Astellas’s ADC Enfortumab Vedotin Logs 44% ORR in Advanced Urothelial Cancer in PII
June 5, 2019
- Amazon Web Services to Enhance Services for Healthcare Industry in Japan
June 5, 2019
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…